METHODS OF TREATING A PULMONARY BACTERIAL INFECTION USING FLUOROQUINOLONES
Disclosed herein are methods of treating a pulmonary bacterial infection comprising bacteria growing under anaerobic conditions using a fluoroquinolone antibiotic. The fluoroquinolone antibiotic may, for example, be levofloxacin or ofloxacin. Also disclosed are methods of inhibiting bacteria growing under anaerobic conditions by exposing the bacteria to an amount of fluoroquinolone antibiotic effective to inhibit growth of said bacteria.
1 . A method of treating a pulmonary bacterial infection comprising administering a therapeutically effective amount of an aerosol of a fluoroquinolone antibiotic selected from the group consisting of levofloxacin and ofloxacin, wherein the pulmonary bacterial infection comprises bacteria growing under anaerobic conditions.
2 . The method of claim 1 , further comprising assaying the pulmonary bacterial infection for the presence of bacteria growing under anaerobic conditions.
3 . The method of claim 1 , wherein the bacteria is capable of growing under anaerobic conditions using nitrate or nitrite.
4 . The method of claim 3 , further comprising assaying the pulmonary bacterial infection for the presence of bacteria capable of growing under anaerobic conditions using nitrate or nitrite.
5 . The method of claim 1 , wherein the bacteria comprises Pseudomonas aeruginosa.
6 . The method of claim 5 , further comprising assaying the pulmonary bacterial infection for the presence of Pseudomonas aeruginosa.
7 . The method of claims 1 , wherein the fluoroquinolone antibiotic is levofloxacin.
8 . The method of claim 1 , wherein the fluoroquinolone antibiotic is ofloxacin.
9 . The method of claim 1 , wherein said pulmonary bacterial infection is identified as having at least a portion of said bacteria growing under anaerobic conditions.
10 . The method of claim 1 , wherein the pulmonary bacterial infection is in a subject with cystic fibrosis.
11 . The method of claim 1 , wherein the pulmonary infection is characterized by sputum comprising nitrate levels of at least 250 μM.
12 . The method of claim 1 , wherein the pulmonary bacterial infection is identified as having sputum comprising nitrate levels of at least 250 μM.
13 . The method of claim 1 , wherein the method of treating the pulmonary bacterial infection does not include administering a therapeutically effective amount of an antibiotic selected from the group consisting of tobramycin, amikacin and aztreonam.
14 . The method of claim 1 , wherein no other antibiotics are administered in a therapeutically effective amount to treat the pulmonary bacterial infection.
15 . The method of claim 1 , wherein the fluoroquinolone antibiotic is administered by intrapulmonary delivery.
16 . The method of claim 1 , where said therapeutically effective amount of fluoroquinolone is more than about 5 mg.
17 . The method of claim 1 , where said therapeutically effective amount of fluoroquinolone is no more than about 150 mg.
18 . A method of inhibiting bacteria growing under anaerobic conditions comprising exposing said bacteria to an amount of a fluoroquinolone antibiotic effective to inhibit the growth of said bacteria.
19 . The method of claim 18 , wherein the bacteria is exposed to a mixture comprising at least about 0.75 mg/L of the fluoroquinolone antibiotic.
20 . The method of claim 18 , wherein the bacteria comprises Pseudomonas aeruginosa.
21 . The method of claim 18 , wherein the bacteria is identified as growing under anaerobic conditions.
22 . The method of claim 18 , further comprising assaying a sample of said bacteria to determine if said bacteria is growing under anaerobic conditions.
23 . The method of claim 18 , wherein a sample of the bacteria is characterized by nitrate levels of at least 250 μM.
24 . The method of claim 18 , wherein the fluoroquinolone antibiotic is levofloxacin.
25 . The method of claim 18 , wherein the fluoroquinolone antibiotic is ofloxacin.